Clinical trial recruitment has become almost exclusively data-driven. Statistics, analytics, algorithms, and performance metrics now shape how studies reach people and how enrollment is measured. Are we so focused on the what (the numbers) that we’re missing the why and the who (the human experience)?
The allure of this data is the promise of efficiency: targeted messaging, reaching the right demographics, and measuring impact with quantitative precision. Numbers tell us who clicked. They rarely tell us who understood.
The Power and Pitfalls of a Data-Only View
Data could easily be the most powerful tool in research. It identifies trends, segments audiences, tracks reach, and A/B tests specific elements of clinical trial messaging. It provides valuable signals.
Where do algorithms fall short? Data that isn’t paired with human understanding faces the following limitations:
- Lack of Context: Data shows what happened (e.g., low click-through rate), but rarely why.
- Missing Nuance & Emotion: Stats can’t capture the fear, hope, skepticism, or practical barriers patients experience when considering a trial.
- Risk of Generic Clinical Trial Messaging: Optimizing based purely on broad data points can lead to impersonal communication that fails to resonate on a human level.
- The ‘Average’ Patient Myth: Data often reflects averages, potentially missing the specific needs or concerns of diverse patient subgroups.
- Optimizing for the Wrong Thing: Are we and the algorithms optimizing for clicks or for genuine understanding and trust?
The Irreplaceable Value of Listening: What Patient Insights Tell Us
Qualitative patient insights give quantitative data its meaning. Neither works well without the other. They must work together to bring real understanding of the people a study hopes to reach.
This qualitative data is often referred to as “soft” data, which makes it seem less important. In fact, this data is critical human intelligence that provides the context, empathy, and relevance missing from raw numbers. Some examples of necessary qualitative data are:
- The language patients use to describe their condition and treatment journey.
- Their core motivations, fears, and hopes related to trial participation.
- The practical and emotional barriers they face.
- Who they trust and where they look for information.
- What kind of support makes a real difference.
Whispers Becoming Louder
The importance of authentic communication is frequently discussed within patient communities and by advocates. Online conversations, for instance on platforms like LinkedIn or Facebook, often feature reflections on recruitment materials, highlighting when clinical trial messaging felt cold, routine or missed the mark versus when it felt genuinely understanding and human, often because patient input was clearly incorporated. This lived experience underscores the need to listen.
I recently wrote the following LinkedIn post in hopes of sparking genuine discussion with researchers and patients alike: We have the data, but are we listening to the people? I’m finding that the clinical trial applications I am reviewing are missing a vital component: the human element when it comes to making patients aware of trials…we seem bogged down in stats and algorithms and this is dictating our messaging…it’s simply not engaging but it does fit “a way of working.”
Yes, we need CTRs above 2%, and conversions above 10%, and 30% or more enrollment from underrepresented groups, but what are those numbers really telling us?
- Use data to inform, not dictate. Numbers are a tool to find people, not the goal.
- Create content that is data driven but ensure it’s human focused.
- Focus on retention, not just recruitment. A person who joins your clinical trial is a person who trusts you because they understand the start, middle and end of the journey. Understanding earlier is what makes staying later possible.
If you want to focus on data, how about this novel approach, ASK the patients what they need, and actually listen.
Harmonizing Data and Dialogue: Practical Steps
Designing good communication isn’t about pleasing stakeholders. It’s about serving participants. The only way to do that well is to listen, learn, and improve, again and again. Listening is not reactive. It’s proactive. It means following up, circling back, and making sure every participant sees how their input made a difference. That kind of engagement pays dividends, not in clicks, but in trust.
- Data Informs, Insights Guide: View data and insights as complementary. Use quantitative data to identify where to look, and qualitative insights to understand what you’re seeing and how to respond.
- Listen First, Message Later: Gather patient insights before creating messaging strategies and recruitment campaigns, not just using patients to test pre-determined messages.
- Co-Creation is Key: Develop recruitment materials with patients, ensuring language, tone, and content resonate and address real concerns.
- Qualitative Exploration: Invest in methods like patient interviews, focus groups, journey mapping, and careful social listening (beyond just sentiment scores).
- Empower Internal Teams: Foster collaboration between data analysts, marketing teams, and patient engagement specialists. Train teams to appreciate and interpret both types of information.
- Feedback Loops: Create mechanisms to gather feedback on recruitment materials and processes directly from potential participants.
The future of clinical research depends on more than new platforms or expanded datasets. It depends on connection, and connection doesn’t come from algorithms. It comes from listening. The best trial strategies won’t just optimize messaging. They’ll change what it is for. They’ll start with real questions, build in space for feedback, and focus on what people care about. They’ll be tested not just for response, but for respect. If that is the kind of study you want to run, see what trialport does for sponsors and CROs.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, a clinical trial navigation and decision-support platform, so that understanding a study comes before anyone is asked to join one. Understanding comes first. Decisions follow.